Skip to main content

BC Cancer – Victoria

If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.

TUMOUR GROUP/SITE TRIAL SUMMARY OPENING DATE
BREAST

Evaluation of the Ductal Carcinoma In Situ Score for Decisions on Radiotherapy in Patients with Low/Intermediate Risk DCIS
(DUCHESS)

Apr 2018

Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer.
(BWEL MAC.20)
Mar 2018
CENTRAL NERVOUS SYSTEM (CNS)
GASTROINTESTINAL (GI)   
GENITOURINARY (GU) - ProstateThis study will examine the use of stereotactic ablative radiotherapy, in which patients are given only a few, high dose radiation treatments. Treatments are short, non-invasive, applicable to patients not able to do brachytherapy, and may be more effective than conventional external beam radiation therapy. 
(ASSERT)
Apr 2016
GENITOURINARY (GU) - Kidney
  
GENITOURINARY (GU) - Bladder
 
GYNE - Ovary IROC - The Immune Response to Ovarian Cancer
(*Deeley Research Centre)
Aug 2007
HEAD AND NECK
LUNG 

LYMPHOMAIROL - The Immune Response to Lymphoma
(*Deeley Research Centre)
Mar 2008
MELANOMA
SARCOMA  
SUPPORTIVE / PALLIATIVE CARE  
SYMPTOM MANAGMENT

A Randomized Phase II/III Study Comparing Stereotactic Body Radiotherapy(SBRT) versus Conventional Palliative Radiotherapy (CRT) for Patients with Spinal Metastases
(SC24)

Nov 2017

MULTI SITE

A non-randomized phase II trial where all participants will receive experimental Stereotactic Ablative Radiotherapy (SABR) to all sites of progressing metastatic disease
(SABR-5/SABR for Oligometastases)


Jan 2017

Personal REsponse Determinants in Cancer Therapy - (PREDICT) Jan 2006
SOURCE: BC Cancer – Victoria ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2018 Provincial Health Services Authority